glp-1 lawsuit Trulicity [2026] On February 2, 2026, Pope

Metseras pipeline includes MET-097i, a GLP-1 receptor agonist designed for once-monthly dosing, and MET-233i, an amylin analog being developed for monthly administration

Sales of antiobesity drugs hit $1.1 billion in the second quarter of 2023.

Type 2 Diabetes Mellitus (T2DM) is one of the most common metabolic disorders worldwide

In fact, the similar pathological mechanisms shared by PD and T2DM have inspired several studies on the therapeutic potential of T2DM drugs against PD, among which glucagon-like peptide-1 receptor (GLP-1R) agonists are promising candidates

2023 May 23;14:1181913

Alex Zhavoronkov, discussed how the GLP-1 revolution is expanding beyond weight loss toward healthy longevity